Patents Assigned to Pfizer
  • Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
    Patent number: 6132774
    Abstract: This invention is directed to pharmaceutical combination compositions and methods comprising (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydr onaphthalene-2-ol or a pharmaceutically acceptable salt thereof and parathyroid hormone or a biologically active fragment thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass and frailty.
    Type: Grant
    Filed: November 15, 1999
    Date of Patent: October 17, 2000
    Assignee: Pfizer Inc.
    Inventors: HuaZhu Ke, David D. Thompson
  • Compositions and methods for decreasing sebum production
    Patent number: 6133326
    Abstract: A method of treating diseases caused by sebaceous gland disorders, in humans and animals, which comprises administering to said humans and animals a composition comprising a sebaceous gland secretion inhibiting amount of an active compound comprising an acyl coA cholesterol acyl transferase (ACAT) inhibitor or prodrug therefor.A composition for use in treating diseases caused by sebaceous gland disorders such as acne in humans and animals which comprises a sebaceous gland secretion inhibiting amount of an acyl coA cholesterol acyl tanferase (ACAT) inhibitor or prodrug therefor and, optionally, a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: August 31, 1994
    Date of Patent: October 17, 2000
    Assignee: Pfizer Inc
    Inventor: James T. Mayne
  • Tetrahydronaphthalene and tetrahydroquinoline compounds, their preparation and their use as leukotriene B.sub.4 (LTB.sub.4) antagonists
    Patent number: 6133286
    Abstract: This invention relates to novel benzopyran and other benzo-fused leukotriene B.sub.4 (LTB.sub.4) antagonists and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds or a pharmaceutically acceptable salt thereof, and to methods of using such compounds as LTB.sub.4 antagonists. The compounds and the pharmaceutically acceptable salts of this invention inhibit the action of LTB.sub.4 and are therefore useful in the treatment of LTB.sub.4 induced illnesses such as inflammatory disorders including rheumatoid arthritis, osteoarthritis, inflammatory bowel disease, psoriasis and other skin disorders such as eczema, erythema, pruritus and acne, stroke and other forms of reperfusion injury, graft rejection, autoimmune diseases, asthma, and other conditions where marked neutrophil infiltration occurs.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: October 17, 2000
    Assignee: Pfizer Inc.
    Inventors: Mark A. Dombroski, Kevin Koch, Anthony D. Piscopio
  • Compounds enhancing antitumor activity of other cytotoxic agents
    Patent number: 6130217
    Abstract: This invention relates to certain heterocyclic compounds and their pharmaceutically acceptable salts, which are useful for sensitizing multidrug-resistant tumor cells to anticancer agents and multidrug resistant forms of malaria, tuberculosis, leishmania and amoebic dysentery to chemotherapeutants. The compounds and their pharmaceutically acceptable salts are also inhibitors of the active drug transport capability of P-glycoprotein which is encoded by the human MDR1 gene, as well as of certain other related ATP-binding-cassette transporters from eukaryotic and prokaryotic organisms (e.g., pfmdr from Plasmodium falciprum, and murine mdr1 and mdr3 gene products).
    Type: Grant
    Filed: September 20, 1995
    Date of Patent: October 10, 2000
    Assignee: Pfizer Inc
    Inventors: Lee Daniel Arnold, Jotham Wadsworth Coe, Takushi Kaneko, Mikel Paul Moyer
  • Insect-repellent formulations
    Patent number: 6130241
    Abstract: The invention provides an insect- or acarid-repellent formulation comprising a compound of formula (I), wherein R represents straight or branched chain C.sub.2-10 alkyl, straight or branched chain C.sub.2-10 alkenyl, or straight or branched chain C.sub.2-10 alkynyl, which groups are optionally substituted by one or more groups selected from halogen, C.sub.4-8 cycloalkyl and C.sub.4-8 cycloalkenyl; and a suitable adjuvant, diluent or carrier.
    Type: Grant
    Filed: March 10, 1999
    Date of Patent: October 10, 2000
    Assignee: Pfizer Inc.
    Inventor: Darren John Schulz
  • Method of treating tourette's syndrome and obsessive compulsive disorder
    Patent number: 6127373
    Abstract: A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.
    Type: Grant
    Filed: September 3, 1998
    Date of Patent: October 3, 2000
    Assignee: Pfizer Inc.
    Inventor: Phillip B. Chappell
  • Substituted indazole derivatives and related compounds
    Patent number: 6127398
    Abstract: The invention relates to compounds of the formula I ##STR1## and pharmaceutically acceptable salts thereof, wherein R.sub.2.sup.a and R.sub.2.sup.b are independently selected from the group consisting essentially of hydrogen and hereinafter recited substituents, provided that one, but not both of R.sub.2.sup.a and R.sub.2.sup.b must be independently selected as hydrogen, wherein said substituents comprise: ##STR2## wherein the dashed lines in formulas (Ia) and (Ib) independently and optionally represent a single or double bond, provided that in formula (Ia) both dashed lines cannot both represent double bonds at the same time; andR, R.sub.1, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.18 and m are as defined.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: October 3, 2000
    Assignee: Pfizer Inc
    Inventor: Anthony Marfat
  • Method of reducing tissue damage associated with non-cardiac ischemia
    Patent number: 6127367
    Abstract: A method of preventing non-cardiac tissue damage resulting from ischemia, comprising administering to a patient in need of such treatment an effective amount of an aldose reductase inhibitor.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: October 3, 2000
    Assignee: Pfizer, Inc.
    Inventors: Thomas A. Beyer, Delvin R. Knight, Jr., Banavara L. Mylari, Peter J. Oates, E. Roy Pettipher, W. Ross Tracey
  • Estrogen agonist/antagonists treatment of atherosclerosis
    Patent number: 6124346
    Abstract: A method of treating atherosclerosis, independent of lipid lowering, in mammals, including humans, in need of treatment by inhibiting progression of an atherogenic lesion or by stabilizing plaque. Such lesion progression inhibition or plaque stabilization is preferably achieved by directly inhibiting chemokine expression leading to excessive inflammatory cell recruitment by administering certain estrogen agonist/antagonists.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventor: Robert J. Aiello
  • Dofetilide polymorphs
    Patent number: 6124363
    Abstract: The invention relates to the substantially pure dofetilide polymorphs P162, P162a and P143, and to processes for the preparation of, compositions containing and to the uses of, such polymorphs.
    Type: Grant
    Filed: November 16, 1999
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventors: Ian Colin Appleby, Trevor Jack Newbury, Gary Nichols
  • Osteoporosis compounds
    Patent number: 6124314
    Abstract: This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.
    Type: Grant
    Filed: September 28, 1998
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Bruce A. Lefker, Robert L. Rosati
  • Heterocyclic compounds
    Patent number: 6124264
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventors: Philip A Carpino, Paul A DaSilva-Jardine, Bruce A Lefker, John A Ragan
  • Heteroaryl amines as novel acetyl cholinesterase inhibitors
    Patent number: 6124321
    Abstract: Compounds of the formula ##STR1## wherein ring A, ring B, ring D, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6,R.sup.11, R.sup.12, R.sup.13, E, G, X and P are as defined below. The compounds of formula I are cholinesterase inhibitors and are useful in enhancing memory in patients suffering from dementia and Alzheimer's disease.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc
    Inventors: Yuhpyng Liang Chen, Arthur Adam Nagel
  • Bicyclo[3.1.0]hexanes and related compounds
    Patent number: 6124361
    Abstract: The present invention relates to compounds of the formula I, as defined in the specification, pharmaceutical compositions containing such compounds the use of such compounds to treat neurological and psychiatric disorders.
    Type: Grant
    Filed: December 29, 1998
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc
    Inventor: Bertrand L. Chenard
  • Process and intermediates for a .beta..sub.3 -adrenergic receptor agonist
    Patent number: 6124457
    Abstract: The instant invention relates to intermediates of Formula II, ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for preparing compounds of Formula III, ##STR2## and enantiomers thereof, wherein R.sup.2, R.sup.3 and R.sup.4 are as defined in the specification. Compounds of Formula II and Formula III are intermediates in the preparation of a potent .beta..sub.3 adrenergic receptor agonist. The instant invention also relates to processes for preparing the .beta..sub.3 adrenergic receptor agonist using the compounds of Formula II and Formula III.
    Type: Grant
    Filed: January 20, 2000
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventors: Keith M. DeVries, Jeffrey W. Raggon, Ravi M. Shanker, Frank J. Urban, Brian C. Vanderplas
  • Triazole antifungal agents
    Patent number: 6124325
    Abstract: An antifungal compound of formula (I): ##STR1## or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of either entity, wherein X is CH or N; R.sup.1 is phenyl substituted with 1 to 3 substituents each independently selected from halo and CF.sub.3 ; R.sup.2 is (hydroxy)C.sub.1 -C.sub.4 alkyl, CONH.sub.2, S(O).sub.m (C.sub.1 -C.sub.4 alkyl), Ar or Het; m is 1 or 2; Ar is phenyl optionally monosubstituted with halo or CF.sub.3 ; and Het is a C-linked 6-membered nitrogen-containing aromatic heterocyclic group containing 1 or 2 nitrogen atoms, or a C- or N-linked 5-membered nitrogen-containing aromatic heterocyclic group containing from 2 to 4 nitrogen atoms, wherein either of said heterocyclic groups is optionally substituted with C.sub.1 -C.sub.4 alkyl or (C.sub.1 -C.sub.4 alkoxy)methyl.
    Type: Grant
    Filed: August 2, 1999
    Date of Patent: September 26, 2000
    Assignee: Pfizer Inc.
    Inventors: Andrew Simon Bell, Peter Thomas Stephenson
  • Apo B-secretion/MTP inhibitory amides
    Patent number: 6121283
    Abstract: This invention is directed to compounds of formula (I) or the stereoisomers, pharmaceutically acceptable salts and hydrates thereof. The compounds are Apo B/MTP inhibitors and are useful in the treatment of various disorders and conditions such as atherosclerosis, pancreatitis, obesity, hypercholesteremia, hypertriglyceridemia, hyperlipidemia, and diabetes. The compounds of this invention are also useful in combination with other pharmaceutical agents including cholesterol biosynthesis inhibitors and cholesterol absorption inhibitors,especially HMG-CoA reductase inhibitors and HMG-CoA synthase inhibitors; HMG-CoA reductase gene expression inhibitors; CETP inhibitors; bile acid sequestrants; fibrates; cholesterol absorption inhibitors; ACAT inhibitors, squalene synthetase inhibitors, ion-exchange resins, anti-oxidants and niacin.
    Type: Grant
    Filed: April 20, 1999
    Date of Patent: September 19, 2000
    Assignee: Pfizer Inc
    Inventors: George Chang, George Joseph Quallich
  • Azabicyclic rotomase inhibitors
    Patent number: 6121280
    Abstract: This invention relates to novel azabicyclic compounds of the formula ##STR1## wherein R.sup.1, Q and Z are defined as in the specification, pharmaceutical compositions containing them, and the use of such compounds for the treatment of neurodegenerative diseases and other disorders involving nerve damage.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: September 19, 2000
    Assignee: Pfizer Inc.
    Inventors: Arthur A. Nagel, James F. Blake
  • Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives
    Patent number: 6121260
    Abstract: Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. Many of the compounds are novel.
    Type: Grant
    Filed: July 2, 1998
    Date of Patent: September 19, 2000
    Assignees: Neurogen Corporation, Pfizer Inc.
    Inventors: Andrew Thurkauf, Jun Yuan, Alan Hutchison, Charles A. Blum, Richard L. Elliot, Marlys Hammond
  • Applicator
    Patent number: D431093
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: September 19, 2000
    Assignee: Pfizer Inc.
    Inventors: Stuart M. Leslie, Charles Curtiss, Chen Jiang